



#### **CERTIFICATE OF MAILING**

Date: 3 1 04 By: LOW // (0)

Attorney Docket No.: 101621-21

### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT

Junji TAKENAKA

SERIAL NO.

10/560,794

CUSTOMER NO.

27387

**FILED** 

December 15, 2005

FOR :

Curable Polycyclic Compounds and Process for the

**Production Thereof** 

ART UNIT

TBA

**EXAMINER** 

: TBA

Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

### INFORMATION DISCLOSURE STATEMENT

SIR:

Pursuant to 37 CFR §§ 1.56, 1.97 and 1.98, Applicants respectfully request that the Examiner consider the references listed on the attached Form PTO-1449.

# I. Timeliness, Fees and Certifications in lieu of Fees

This information disclosure statement is being filed within three months of the filing date of the application, or within three months of entry into the national stage, or before the mailing of a first Office Action on the merits. Pursuant to 37 CFR § 1.97(b), consideration of this information disclosure statement does not require a fee or a statement under 37 CFR § 1.97(e). However, should the Assistant Commissioner determine that a fee is, in fact, due, the Assistant Commissioner is hereby authorized to charge the fee to Deposit Account No. 14-1263.

# II. Copies of Listed References

Copies of all references listed on the attached Form PTO-1449 are being supplied.

Copies of U.S. patents are not included pursuant to Pre-OG Notice dated July 11, 2003.

## III. Concise Statement of Relevance

A concise statement of the relevance of all references listed on the attached Form PTO-1449 that are *not in the English language*, is being provided on a separate sheet.

Consideration of the foregoing in relation to this application is respectfully requested.

Respectfully submitted,

NORRIS MCLAUGHLIN & MARCUS, P.A.

Bruce S. Londa

Reg. No. 33,531

875 Third Avenue

18<sup>th</sup> Floor

New York, New York 10022

(212) 808-0700

APPLICANT'S INFORMATION  Applica  Applica					rney Docket: 101621-	21	Serial No.: 10/560,794  Examiner: TBA  Group: TBA			
					licant: Junji TAKENA	KA				
					g Date: December 15,	2005				
PADEMBKOF			S. PATEN	ΓDO	CUMENTS					
Examiner's Initial		Document Number	· Date	e	Name	Clas	Sub Class	Filing Dat		
		FORE	EIGN PAT	ENT	DOCUMENTS					
		Document Number	Date	e	Country	Class	Sub Class	Tran Yes	slation No	
	AA	3-118342	5/20/91		Japan	C07C	29/124	X		
	AB	2-196744	8/3/90		Japan	C07C	35/37	X		
	AC	10-286467	10/27/98		Japan	B01J	31/02	X		
	AD	9-327626	12/22/97		Japan	B01J	31/26	X		
	AE	8-38909	2/13/96		Japan	B01J	31/06	X		
	AF	2001-26563	1/30/01		Japan	C07C	29/86	X		
	AG	2000-219646	8/8/00		Japan	C07C	29/48	X		
<del></del>	AH	2-104553	4/17/90		Japan	C07C	69/03	X		
	AI	2000-327994	11/28/00		Japan	C09D	175/04	X		
	AJ	2000-327950	11/28/00		Japan	C09D	4/00	X		
	AK	63-307844	12/15/88		Japan	C07C	69/54	X		
	AL	60-100537	6/4/85		Japan	C07C	69/007	X		
	C	     THER PRIOR ART (Ir	cluding A	uthoi	; Title, Date, Pert	inent Pa	ges, Etc.)			
	AM	Shiryaev, et al.; "The Effect of Solvent Polarity on the Conformational Equilibrium in Glycidyl and Thioglycidyl Esthers and Esters"; V.V. Kuibyshev Samarsk Polytechnical Institute; Volume 27, No. 6, June 1991, Pages 1249-1253.								
	AN	Butenko, et al.; "Synthesis of 2,2-(Adamantylene-1,3)-Diethanoic Acids"; The Volgograd Polytehnical Institute; A.V. Topchiev Institute of Petrochemical Synthesis, Russian Academy o Sciences, Moscow, 117912; Pages 1612-1615.								
	AO	Aigami, et al.; "Biologically Active Polycycloalkanes. 1. Antiviral Adamantane Derivaties"; Polycycloalkanes; Journal of Medicinal Chemistry; 1975, Volume 18, No. 7, Pages 713-721.								
EXAMINER:					DATE CONSIDERED:					